Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Cardiology ; 122(2): 83-8, 2012.
Article in English | MEDLINE | ID: mdl-22739496

ABSTRACT

OBJECTIVES: Acute ST elevation myocardial infarction (STEMI) presenting with cardiogenic shock (CS) is associated with dismal prognosis. In the last years, significant advances have been made in reperfusion techniques and pharmacological treatment. Therefore, we aimed to assess the outcome of these patients during the past decade and identify major factors that impact their prognosis. METHODS: We identified 170 patients who presented with STEMI, CS, and underwent primary percutaneous coronary intervention (PCI) between 2001 and 2011. Patients were allocated into two groups based on period of presentation: 2001-2005 (n = 70) and 2006-2011 (n = 100). Clinical outcomes up to 6 months were evaluated. RESULTS: Patients in the latter period were younger, and had lower rates of renal failure and higher rates of stent use. Despite these differences, mortality did not differ and remained high in both periods (52-59% at 6 months). Time frames from onset of symptoms to arrival to the emergency department and to performance of coronary intervention were similar in both periods. Intra-aortic balloon pump use was similar in both periods. In multivariate analysis, factors associated with 1-month mortality were: diabetes (OR = 3.6, 1.4-9.4, p = 0.007), LVEF <40% (OR = 1.8, 1.3-2.6, p = 0.001), GFR <60 ml/min/m(2) (OR = 1.8, 1.3-2.4, p < 0.009) and glycoprotein IIb/IIIa inhibitor use (OR = 0.5, 0.2-1.1, p = 0.08). The combination of diabetes and renal failure was associated with particularly high mortality. CONCLUSIONS: Prognosis of patients presenting with STEMI, CS, and treated with primary PCI during the past decade, remains poor. Better risk-stratification may help improve their grave outcome.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/complications , Shock, Cardiogenic/complications , Aged , Aged, 80 and over , Diabetic Angiopathies/complications , Diabetic Angiopathies/therapy , Diabetic Nephropathies/complications , Female , Hospitalization , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Myocardial Infarction/therapy , Prospective Studies , Treatment Outcome
2.
Cardiovasc Revasc Med ; 13(3): 167-71, 2012.
Article in English | MEDLINE | ID: mdl-22475867

ABSTRACT

BACKGROUND: Manual coronary thrombus aspiration was associated with improved outcomes of ST-elevation myocardial infarction (STEMI) patients. We aimed to evaluate the outcome of aspiration in a "real-world" setting of primary percutaneous coronary intervention (PPCI). METHODS AND MATERIALS: We analyzed the outcome of STEMI patients who underwent PPCI (initial Thrombolysis in Myocardial Infarction flow grade 0/1), comparing patients who underwent aspiration (ASP) to those who had standard (STD) therapy. Various subgroups outcomes were further analyzed. Clinical end points included mortality and major adverse cardiovascular events (MACE) at 30 days and at 1 year. RESULTS: One thousand thirty-five consecutive patients were included: 189 (18.26%) with ASP and 846 (81.74%) with STD. ASP patients were younger (58±12 vs. 61±13, P<.05) and had higher incidence of direct stenting compared to STD patients (34% vs. 16.7%, P<.05). No significant differences were noted in the outcome of ASP vs. STD at 30 days (mortality rate 4.2% vs. 4.5%, P=.9; MACE 6.9% vs. 9.8%, P=.2) and at 1 year (mortality rate 8.0% vs. 8.3%, P=.9; MACE 20.0% vs. 22.3%, P=.5). A significant advantage in favor of ASP was evident in patients with proximal culprit lesions, anterior infarcts, and right ventricular involvement. CONCLUSIONS: Although this was largely a negative study, when STEMI involved a large jeopardized myocardium, aspiration was associated with sustained improved clinical outcomes.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Thrombosis/therapy , Myocardial Infarction/therapy , Thrombectomy , Aged , Angioplasty, Balloon, Coronary/adverse effects , Angioplasty, Balloon, Coronary/mortality , Cardiovascular Diseases/etiology , Chi-Square Distribution , Coronary Angiography , Coronary Thrombosis/complications , Coronary Thrombosis/diagnostic imaging , Coronary Thrombosis/mortality , Female , Humans , Israel , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/etiology , Myocardial Infarction/mortality , Propensity Score , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Suction , Thrombectomy/adverse effects , Thrombectomy/methods , Thrombectomy/mortality , Time Factors , Treatment Outcome
3.
Am J Cardiol ; 109(11): 1563-8, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-22440117

ABSTRACT

Clinical trial data have supported the safety and efficacy of drug-eluting stents (DES) in the treatment of patients with ST-segment elevation myocardial infarctions (STEMIs), but contemporary "real-world" registry data regarding the late safety profiles of DES are limited. This prospective registry-based study included 1,569 consecutive unselected patients with STEMIs who underwent emergency primary percutaneous coronary intervention from January 2001 to December 2009. Of the study cohort, 200 patients (12.7%) received DES, while 1,369 patients (87.3%) underwent bare-metal stent (BMS) placement. The primary end points of the study were all-cause mortality and target vessel revascularization at 1, 2, and 3 years. Survival status was assessed by municipal civil registries. Repeat revascularization procedures were prospectively collected in the hospital database. All-cause mortality was significantly lower in the DES group at 3 years (4.2% vs 13.5%, p = 0.007) compared to BMS-treated patients, but DES use was not an independent predictor of all-cause mortality (adjusted odds ratio 0.5, 95% confidence interval 0.2 to 1.2, p = 0.10). Target vessel revascularization was significantly lower in the DES group compared to the BMS group at 3 years (10.5% vs 21%, p = 0.001). DES use was an independent predictor of reduced target vessel revascularization (adjusted odds ratio 0.44, 95% confidence interval 0.25 to 0.77, p = 0.004). Late definite stent thrombosis occurring after 1 year occurred in 4 (2.5%) patients in the DES group compared to 6 (0.7%) in the BMS group (p = 0.05). DES use was an independent predictor of late stent thrombosis (adjusted odds ratio 8.6, 95% confidence interval 1.9 to 38, p = 0.004). In conclusion, this contemporary registry-based study of patients who underwent primary percutaneous coronary intervention for STEMI demonstrated improved revascularization rates without increased 3-year hazard of adverse clinical outcomes in DES-treated patients.


Subject(s)
Angioplasty, Balloon, Coronary , Drug-Eluting Stents , Myocardial Infarction/therapy , Stents , Coronary Stenosis/mortality , Coronary Stenosis/therapy , Coronary Thrombosis/epidemiology , Diabetes Mellitus/epidemiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/mortality , Platelet Glycoprotein GPIIb-IIIa Complex/therapeutic use , Propensity Score , Prospective Studies , Recurrence , Registries , Renal Insufficiency/epidemiology , Retreatment
4.
Catheter Cardiovasc Interv ; 79(4): 615-22, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22162218

ABSTRACT

OBJECTIVES: To explore the long-term results following implantation of drug-eluting stents (DES) in bifurcation lesions according to contemporary "real world" practice. BACKGROUND: Limited information is available on the long-term outcomes of patients with bifurcation lesions who are treated using DES. A systematic approach for bifurcation lesion management was applied, using either a "provisional" single stent technique or a dedicated two stents strategy according to the side-branch diameter and severity of its ostial stenosis. METHODS: Four hundred one consecutive patients underwent bifurcation percutaneous coronary intervention (PCI) using DES and were included in our prospective registry. All adverse events were recorded up to 2 years and distinguished according to the planned PCI strategy (e.g., one versus two stents technique). RESULTS: A planned two stents strategy was used in 141 patients (35% of patients). In 260 patients (65%), the planned treatment involved stenting of the main branch only with "provisional" stenting of the side-branch according to procedural course. Thus, 24 patients (9.2%) needed additional stenting at the side-branch to complete the PCI. Cumulative major adverse cardiac event rate at 1 and 2 years was similar for both groups (11.4% vs. 14.8% at 1 year and 19.4% vs. 25.7% at 2 years for the single vs. two stents groups, accordingly, P = NS for both). Likewise, there was no difference in mortality, cardiac mortality, myocardial infarction, need for target lesions or target vessel revascularization, or definite stent thrombosis rate between the two groups at 6, 12, and 2 years follow-up. The rate of angiographically confirmed (i.e., definite) stent thrombosis did not differ between the two groups during follow-up. CONCLUSIONS: Our study revealed favorable long-term clinical results following DES implantation using a systematic, rather simplified approach towards bifurcation stenting and using either a single or double stenting technique.


Subject(s)
Angioplasty, Balloon, Coronary/instrumentation , Coronary Stenosis/therapy , Drug-Eluting Stents , Aged , Angioplasty, Balloon, Coronary/adverse effects , Angioplasty, Balloon, Coronary/mortality , Coronary Angiography , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/etiology , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/mortality , Female , Humans , Israel , Kaplan-Meier Estimate , Male , Middle Aged , Myocardial Infarction/etiology , Prosthesis Design , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Thrombosis/diagnostic imaging , Thrombosis/etiology , Time Factors , Treatment Outcome
5.
Isr Med Assoc J ; 12(5): 273-6, 2010 May.
Article in English | MEDLINE | ID: mdl-20929078

ABSTRACT

BACKGROUND: The best therapeutic alternative for patients suffering from in-stent restenosis after drug-eluting stent implantation remains to be elucidated. OBJECTIVE: To characterize the pattern, treatment and outcomes of DES-related in-stent restenosis in patients treated at our institution. METHODS: We determined the incidence and major adverse clinical events in 71 consecutive patients with DES failure among 2473 patients who were treated with 2548 drug-eluting stents between 2004 and 2007. We analyzed the clinical data, procedural parameters and clinical outcomes. RESULTS: The type and number of stents implanted were as follows: Cypher (n = 1808), Endeavor (421) and Taxus (319); of these, 53 (2.9%), 10 (2.4%), and 8 (2.5%) patients respectively presented with restenosis. The mean time to restenosis was 11.3 +/- 9.9 months. Patients' mean age was 65 +/- 11 years; 75% were male, and 68% had diabetes mellitus. Unstable angina was the clinical presentation in 52 (73%). At 6 months, 3 patients had developed myocardial infarction (4.2%), repeat restenosis at follow-up was diagnosed in 8 patients (11.3%), the overall major adverse clinical events rate was 18.3% (13 patients), and 2 patients died (2.8%). CONCLUSIONS: Drug-eluting stent-related restenosis is relatively infrequent but remains a clinical challenge. It occurs more frequently in complex lesion subsets, but the overall intermediate-term prognosis is tolerable.


Subject(s)
Coronary Restenosis/therapy , Drug-Eluting Stents , Graft Occlusion, Vascular/therapy , Aged , Angina, Unstable/complications , Angioplasty, Balloon/statistics & numerical data , Coronary Angiography/statistics & numerical data , Coronary Restenosis/complications , Diabetes Mellitus , Female , Follow-Up Studies , Graft Occlusion, Vascular/complications , Graft Occlusion, Vascular/diagnostic imaging , Humans , Male , Myocardial Infarction/complications , Prospective Studies , Survival Analysis , Treatment Outcome
6.
Am J Cardiol ; 105(4): 435-40, 2010 Feb 15.
Article in English | MEDLINE | ID: mdl-20152235

ABSTRACT

Anemia is a well-known predictor of a poor outcome in patients with ST-segment elevation myocardial infarction (STEMI). In contrast, data relating erythrocytosis to clinical outcomes in patients with STEMI are limited. Because erythrocytosis predisposes to a prothrombotic state, we hypothesized it would be associated with an increased risk of thrombotic complications in patients with STEMI undergoing primary percutaneous coronary intervention. We studied 1,042 consecutive patients with STEMI who underwent primary percutaneous coronary intervention and were a part of our primary percutaneous coronary intervention registry from 2001 to 2007. Patients with cardiogenic shock and late arrival were excluded. Patients were allocated into 3 groups according to their baseline hematocrit: anemia (<36% for women and <39% for men), normal, erythrocytosis (>46% for women and >47% for men). The clinical outcomes were assessed at 1, 6, and 12 months. The patients with anemia had the greatest clinical risk profile. Patients with erythrocytosis had a lower risk profile than the other 2 groups, except for greater rates of smoking. The mortality rates were greatest among the patients with anemia, followed by the patients with erythrocytosis, who in turn had greater short-term mortality than patients with normal hematocrit. Multivariate analysis, which included patients with erythrocytosis and those with normal hematocrit (excluding the patients with anemia), revealed that erythrocytosis was associated with an odds ratio of 4.3 (95% confidence interval 1.4 to 13, p = 0.01) for 1-month mortality. In conclusion, although not as strong a predictor of mortality as anemia, erythrocytosis might be associated with increased short-term mortality compared to a normal hematocrit. The measurement of hematocrit can be used as a useful prognostic marker in patients with STEMI.


Subject(s)
Anemia/diagnosis , Heart Conduction System/physiopathology , Hematocrit , Myocardial Infarction/diagnosis , Polycythemia/diagnosis , Aged , Anemia/etiology , Anemia/mortality , Angioplasty, Balloon, Coronary , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anticoagulants/therapeutic use , Biomarkers/blood , Confidence Intervals , Drug Therapy, Combination , Electrocardiography , Female , Follow-Up Studies , Humans , Israel/epidemiology , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/complications , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Myocardial Infarction/therapy , Odds Ratio , Platelet Aggregation Inhibitors/therapeutic use , Polycythemia/etiology , Polycythemia/mortality , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Factors , Severity of Illness Index , Smoking/adverse effects , Survival Rate
7.
Catheter Cardiovasc Interv ; 74(6): 837-43, 2009 Nov 15.
Article in English | MEDLINE | ID: mdl-19626693

ABSTRACT

AIMS: Given the anecdotal reports and case series suggesting that drug-eluting coronary stents [DES] may be still vulnerable to coronary thrombosis after six months, we sought to assess this risk in patients undergoing non-cardiac surgery six months after stenting. METHODS AND RESULTS: Linking the Rabin Medical Centre interventional cardiology database with its non-cardiac surgical database, we identified 78 patients who underwent DES placement and subsequently [after six months] had noncardiac surgery [15-vascular, 37- abdominal and genitourinary and 26-others, excluding ophthalmic surgery]. Outcome measures included 30-day rate of postoperative myocardial infarction (MI), DES-related thrombosis, and cardiac mortality. Major adverse cardiac events [death and non-fatal MI] occurred in 6 (7.7%) patients including 2 cardiac deaths (2.6%), 4 (5.1%) non-fatal myocardial infarctions (MIs). Two patients (2.6%) sustained stent thrombosis [one patient had 'definite' and one 'probable' stent thrombosis]. All MIs [including stent thrombosis] occurred in the vascular and abdominal surgery group. Two of the MIs events occurred while the patients were on dual antiplatelet agents. IN CONCLUSIONS: Perioperative cardiac events during non cardiac surgery after six months of DES deployment still occur. These cardiac complications [not entirely prevented by continued dual antiplatelet agents] remain a matter of diagnostic and therapeutic challenge and concern.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Artery Disease/therapy , Coronary Thrombosis/etiology , Drug-Eluting Stents/adverse effects , Elective Surgical Procedures/adverse effects , Myocardial Infarction/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Angioplasty, Balloon, Coronary/instrumentation , Angioplasty, Balloon, Coronary/mortality , Child , Child, Preschool , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Thrombosis/diagnostic imaging , Coronary Thrombosis/mortality , Databases as Topic , Elective Surgical Procedures/mortality , Female , Humans , Incidence , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/mortality , Platelet Aggregation Inhibitors/therapeutic use , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Young Adult
8.
Cardiovasc Revasc Med ; 10(2): 88-93, 2009.
Article in English | MEDLINE | ID: mdl-19327670

ABSTRACT

BACKGROUND: Major bleeding is one of the most frequent procedural-related complications of primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infraction (STEMI). We investigated the incidence, predictors, and prognostic impact of peri-procedural bleeding in a cohort of unselected patients undergoing contemporary primary PCI. METHODS: A total of 831 consecutive patients who underwent primary PCI between 1/2001 and 6/2005 were studied. Major bleeding was defined as hemorrhagic stroke, hemoglobin (Hb) drop of >5 g%, or 3-5 g% with a need for blood transfusion. Clinical outcomes were evaluated at 30 days and 6 months. RESULTS: Major bleeding occurred in 27 patients (3.5%). Those who experienced major bleeding were older (66+/-15 vs. 61+/-13, P=.02), more frequently female gender (48% vs. 27%, P=.0001), presented more often with cardiogenic shock (37% vs. 8%, P=.0001), and had higher CADILLAC score (7.8+/-4.5 vs. 5.1+/-4.0, P=.002) and activated clotting time (ACT) levels (284+/-63 vs. 248+/-57 s, P=.007). In multivariate analysis, significant predictors of major bleeding were female gender (OR 5.1, 95% CI 1.7-15.2, P=.004), ACT levels >250 s (OR 3.6, 95% CI 1.1-12.1, P=.04), and use of intra-aortic balloon pump (IABP) (OR 3.5, 95% CI 1.0-12.1, P=.047). Major bleeding was associated with increased 6-month mortality rates (37% vs. 10%, P=.0001), which remained significant after adjustment for baseline CADILLAC score (37% vs. 19.4%, P=.05). CONCLUSIONS: Major bleeding complicating primary PCI is associated with increased 6-month mortality. Women and those who need IABP support are at particularly high risk. Tight monitoring of anticoagulation may reduce the risk of bleeding.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Blood Loss, Surgical , Myocardial Infarction/therapy , Postoperative Hemorrhage/etiology , Age Factors , Aged , Aged, 80 and over , Anticoagulants/therapeutic use , Blood Loss, Surgical/prevention & control , Blood Transfusion , Female , Humans , Incidence , Intra-Aortic Balloon Pumping/adverse effects , Logistic Models , Male , Middle Aged , Myocardial Infarction/mortality , Odds Ratio , Postoperative Hemorrhage/mortality , Postoperative Hemorrhage/prevention & control , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Sex Factors , Time Factors , Whole Blood Coagulation Time
9.
Am J Cardiol ; 103(2): 165-9, 2009 Jan 15.
Article in English | MEDLINE | ID: mdl-19121430

ABSTRACT

Beyond lipid-lowering effects, statins have favorable effects on platelets, endothelial function, plaque stability, and inflammation. These "pleiotropic" effects could contribute to microvascular function preservation during ischemia. Data are limited about the impact of previous treatment with statins on outcomes of patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Accordingly, the aim was to evaluate the effect of previous statin treatment on clinical outcomes of such patients. A total of 950 consecutive patients with STEMI treated with primary PCI who were included in our primary PCI registry from January 2001 to July 2007 were studied. Excluded were patients with cardiogenic shock. Patients were allocated into 2 groups: those who received previous statin treatment (n=327) and those who did not (n=623). Patients who received previous statin treatment were older and more likely to be women; have diabetes, hypertension, hyperlipidemia, renal insufficiency, and anemia; or have had a previous myocardial infarction. Procedural characteristics were similar between the 2 groups. Despite the higher risk profile, patients who received previous statin treatment had a lower 30-day mortality rate (1.5% vs 3.8%; p=0.05). However, at 6 months, mortality differences were no longer evident and patients who received previous statin therapy had a higher rate of target-vessel revascularization (12.4% vs 7.6%; p=0.02). Multivariate analysis showed that previous statin treatment was associated with an odds ratio of 0.4 (95% confidence interval 0.13 to 0.96, p=0.045) for 30-day mortality. In conclusion, the present study suggested that previous therapy with statins in patients with STEMI treated using primary PCI may be associated with reduced short-term mortality.


Subject(s)
Angioplasty, Balloon, Coronary , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Myocardial Infarction/therapy , Angioplasty, Balloon, Coronary/mortality , Chi-Square Distribution , Coronary Angiography , Female , Humans , Israel/epidemiology , Logistic Models , Male , Middle Aged , Myocardial Infarction/diagnosis , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Prospective Studies , Registries , Treatment Outcome
10.
EuroIntervention ; 4(1): 108-14, 2008 May.
Article in English | MEDLINE | ID: mdl-19112787

ABSTRACT

AIMS: There are limited data regarding clinical outcomes of drug-eluting stents (DES) in saphenous vein grafts (SVGs) compared to bare metal stents (BMS). Here we compared outcomes of DES in de novo SVG lesions versus BMS in contemporary percutaneous coronary intervention (PCI). METHODS AND RESULTS: We compared in-hospital, 6-month, 1-year and two years outcomes in 68 patients (72 grafts) who underwent PCI of SVG lesions using DES and a control BMS group composed of 43 patients (46 grafts) who underwent angioplasty in de novo SVG lesions. Major adverse cardiac events (MACE) included death, myocardial infarction (MI), target lesion revascularisation (TLR), and target vessel revascularisation (TVR). The rates of TLR and TVR at the 1-year evaluation were lower in the DES group than the BMS group (TLR per patient, 7.4% vs. 21%, P=0.04; TVR per patient, 10.3% vs. 23.3%, P=0.1). MACE-free survival was 88.2% in the DES group and 69.8% in the BMS group (P=0.02). At two years clinical follow-up: death 2.9% vs. 4.7% (P=0.6); MI: 8.8% vs. 7% (P=0.6). The rates of TLR and TVR were significantly lower in the DES group compared to the BMS group (TLR per patient, 14.7% vs. 32.6%, P=0.03; TVR per patient, 10.3% vs. 27.9%, P=0.02). The rate of MACE-free survival was 79.4% in the DES group and 58.1% in the BMS group (P=0.02). Between one to two years after PCI, no cases of angiographic stent thrombosis were recorded in either group. CONCLUSIONS: DES implantation in SVG lesions was safe and had favourable outcomes after two years without excess cardiac mortality.


Subject(s)
Angioplasty, Balloon, Coronary , Coronary Artery Disease/therapy , Coronary Restenosis/therapy , Drug-Eluting Stents , Graft Occlusion, Vascular/therapy , Saphenous Vein/transplantation , Aged , Angioplasty, Balloon, Coronary/mortality , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/mortality , Female , Follow-Up Studies , Graft Occlusion, Vascular/mortality , Humans , Logistic Models , Male , Metals , Middle Aged , Myocardial Infarction/mortality , Retrospective Studies , Survival Rate , Treatment Outcome
11.
Am J Cardiol ; 102(1): 6-11, 2008 Jul 01.
Article in English | MEDLINE | ID: mdl-18572028

ABSTRACT

Accurate risk stratification has an important role in the management of patients with acute coronary syndromes. Even in patients with ST-elevation acute myocardial infarction (STEMI), for whom early therapeutic options are well defined, risk stratification has an impact on early and late therapeutic decision making. We aimed to compare the prognostic value of 4 risk scores used to evaluate patients with STEMI. We conducted a prospective registry of all patients treated with primary percutaneous coronary intervention for STEMI from January 2001 to June 2006. Excluded were patients with cardiogenic shock. A total of 855 consecutive patients were included in the analysis (age 60.5 +/- 13 years, 19% women, 28% with diabetes, and 48% with anterior wall myocardial infarction). For each patient, the Thrombolysis In Myocardial Infarction (TIMI), Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC), Primary Angioplasty in Myocardial Infarction (PAMI), and Global Registry for Acute Coronary Events (GRACE) risk scores were calculated using specific clinical variables and angiographic characteristics. Thirty-day and 1-year clinical outcomes were assessed. The predictive accuracy of the 4 risk scores was evaluated using the area under the curve or C statistic method. The CADILLAC, TIMI, and PAMI risk scores all had relatively high predictive accuracy for 30-day and 1-year mortality (C statistic range 0.72 to 0.82), with slight superiority of the CADILLAC score. These 3 risk scores also performed well for prediction of reinfarction at 30 days (C statistic range 0.6 to 0.7). The GRACE score did not perform as well and had low predictive accuracy for mortality (C statistic 0.47). In conclusion, risk stratification of patients with STEMI undergoing primary percutaneous coronary intervention using the CADILLAC, TIMI, or PAMI risk scores provide important prognostic information and enables accurate identification of high-risk patients.


Subject(s)
Angioplasty, Balloon, Coronary , Fibrinolytic Agents/therapeutic use , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Thrombolytic Therapy , Aged , Electrocardiography , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnosis , Predictive Value of Tests , Risk Assessment , Risk Factors , Severity of Illness Index , Treatment Outcome
12.
Catheter Cardiovasc Interv ; 70(7): 937-43, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-17621664

ABSTRACT

BACKGROUND: There are few data about percutaneous coronary interventions (PCI) in nonagenarians (patients aged > or =90 years). This study aimed to assess acute and intermediate term clinical outcomes among nonagenarian patients undergoing PCI. METHODS: The study included 65 consecutive patients, age > or =90 years undergoing PCI between January 2001 and August 2006. Fourteen patients were admitted with acute ST elevation acute myocardial infarction (STEAMI), one had cardiogenic shock, 39 patients sustained non-STEAMI, and 12 patients were with severe stable angina pectoris. Procedural data, in-hospital, and six-month clinical outcomes were obtained and adjudicated for all patients. RESULTS: Coronary angiography documented multivessel disease in 86% of patients with relatively complex lesions (type B or C) in 94% treated using stent deployment in 92% of patients. In 7% of cases IABP was needed. Immediate procedural success was achieved in 92% patients. Cumulative mortality at hospital discharge and by 30-days was 14% and increased to 18% at 6-months follow-up. Total major adverse cardiac events (MACE: death, AMI, TVR, stroke) was 17% at hospital discharge and increased to 21% by 6-months. Stroke was documented in one patient (1.5%) at hospital discharge. Cumulative mortality at 6 month was 0% in patients with stable angina and 23% in emergent PCI scenario (AMI or NSTEAMI or ACS). Univariate analysis revealed that emergent PCI, systolic blood pressure, left ventricular ejection fraction, diabetes mellitus, renal failure, TIMI flow at baseline, and procedural success, are all correlative with 6-months mortality. CONCLUSION: We conclude that clinically stable nonagenarian patients with coronary artery disease undergoing PCI have excellent PCI related prognosis while clinically unstable patients have a worse outcome. Thus, careful attention to background medical history and clinical presentation should dictate the prognosis and/or management among nonagenarian patients.


Subject(s)
Aging , Angioplasty, Balloon, Coronary/adverse effects , Cardiovascular Diseases/etiology , Coronary Artery Disease/therapy , Health Services for the Aged , Age Factors , Aged, 80 and over , Angioplasty, Balloon, Coronary/instrumentation , Blood Pressure , Cardiovascular Diseases/mortality , Cardiovascular Diseases/physiopathology , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Coronary Circulation , Diabetes Complications/etiology , Diabetes Complications/mortality , Emergency Service, Hospital , Hospital Mortality , Humans , Patient Selection , Renal Insufficiency/complications , Research Design , Retrospective Studies , Risk Assessment , Risk Factors , Stents , Stroke Volume , Time Factors , Treatment Outcome , Ventricular Function, Left
13.
Am J Cardiol ; 99(4): 442-5, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17293180

ABSTRACT

No-reflow is a frequent event during percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), and it may affect cardiac prognosis. We evaluated the occurrence of no-reflow as a predictor of outcomes in patients who underwent PCI for AMI. We prospectively collected data from 599 consecutive patients who underwent stent-based PCI for ST-elevation AMI by identifying those with no-reflow (Thrombosis In Myocardial Infarction [TIMI] grade <3 flow at completion of the procedure) and analyzing their baseline characteristics and clinical outcomes. Patients with no-reflow (n = 40, 6.7%) were older (67 +/- 13 vs 60 +/- 13 years, p = 0.002) and had longer ischemic times (5.5 +/- 3.7 vs 4.4 +/- 3.0 hours, p = 0.04) with more TIMI grade 0/1 flow at presentation (90% vs 64%, p = 0.001). No-reflow occurred mostly (73%) after stenting and often required intra-aortic balloon pump counterpulsation (30% vs 4.3%, p <0.001). Peak creatine kinase level was higher in patients with no-reflow (2,700 +/- 1,900 vs 2,000 +/- 1,800, p = 0.03) and more often associated with moderate or severe left ventricular dysfunction (68% vs 45%, p = 0.006) and increased 6-month mortality (12.5% vs 4.3%, p = 0.04). By multivariate analysis, no-reflow was an independent predictor of long-term mortality (odds ratio 3.4, p = 0.02). In addition, renal failure (odds ratio 4.39, p = 0.0025) and preprocedure TIMI grade 0/1 flow (odds ratio 2.1, p = 0.003) were independent predictors of no-reflow. In conclusion, the association of no-reflow with longer ischemic time and worse initial TIMI flow may indicate the presence of highly organized thrombus burden with higher propensity for distal embolization. Regardless of its mechanism, no-reflow was an independent predictor of increased mortality.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Stents , Chi-Square Distribution , Coronary Angiography , Female , Humans , Logistic Models , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/physiopathology , Prognosis , Prospective Studies , Treatment Outcome
14.
Catheter Cardiovasc Interv ; 69(3): 395-400, 2007 Feb 15.
Article in English | MEDLINE | ID: mdl-17195964

ABSTRACT

BACKGROUND: Renal insufficiency (RF) was shown to be associated with a worsened prognosis following acute myocardial infarction (AMI). OBJECTIVES: The authors analyzed the outcomes of AMI patients with impaired renal function tests treated using primary percutaneous coronary intervention (PCI), to determine factors associated with increased mortality risk. METHODS: This study included 558 consecutive AMI patients treated using primary PCI between January 2001 and June 2005. The authors compared outcome results according to glomerular filtration rate (GFR). An abbreviated equation was used to calculate GFR. Patients were grouped as follow: normal (> or =90 mL/min/1.73 m(2)), mildly impaired (60-89 mL/min/1.73 m(2)), moderately impaired (30-59 mL/min/1.73 m(2)), and severely impaired GFR (< 30 mL/min/1.73 m(2)). RESULTS: There was a stepwise increase in 30-day mortality among patients with normal, mildly, moderately, and severely impaired RF: 2.1%, 3.7%, 8.2%, and 22.2%, respectively (P = 0.004). Seventeen out of the 324 with any degree of RF died within 1 month [5.3%] of these nine patients [53%] died because of cardiac cause. Univariate correlation analysis, factors associated with an increased risk of 1 month mortality included: age > 75 years, left ventricular ejection fraction < 35%, lower GFR, killip class > 1, multivessel coronary artery disease, failure to achieve TIMI flow grade = 3, the occurrence of no-reflow, IABP use, lack of administration of anti GP 2b/3a. The amount of contrast media used during the procedure [mL/Kg] as well as renal function deterioration were also associated with increased mortality. CONCLUSIONS: Clinical and angiographic parameters collected before and during PCI can be used to predict 30-day mortality among AMI patients with RF. Findings indicate that in the setting of contemporary catheter-based reperfusion strategy for AMI, the extent of coronary artery disease, measures of PCI complexity, and degree of renal impairment prior/following the procedure are altogether related to mortality.


Subject(s)
Angioplasty, Balloon, Coronary , Emergency Treatment , Myocardial Infarction/physiopathology , Myocardial Infarction/therapy , Renal Insufficiency/physiopathology , Aged , Aged, 80 and over , Analysis of Variance , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Coronary Artery Disease/therapy , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Israel/epidemiology , Logistic Models , Male , Middle Aged , Myocardial Infarction/complications , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/mortality , Predictive Value of Tests , Prospective Studies , Renal Insufficiency/complications , Renal Insufficiency/mortality , Research Design , Risk Factors , Severity of Illness Index , Stroke Volume , Survival Analysis , Treatment Outcome , Ventricular Function, Left
15.
Am Heart J ; 153(2): 231-7, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17239681

ABSTRACT

BACKGROUND: Right ventricular (RV) involvement during acute inferior myocardial infarction (MI) is associated with increased early morbidity and mortality. With recent improvement in percutaneous coronary intervention (PCI) techniques, it is unclear which factors may improve the outcomes of these patients. We sought to assess the prognostic significance of the presence of right ventricular myocardial infarction (RV-MI) in patients undergoing primary PCI and to explore factors associated with improved outcomes by using a large database representing the "real life" of patients with acute MI (AMI) treated by primary PCI. METHODS: We analyzed our database of patients with AMI undergoing primary PCI within 12 hours of chest pain between January 2001 and June 2005, excluding patients with cardiogenic shock. RESULTS: Of the 666 consecutive patients with MI fulfilling our inclusion criteria, 329 had anterior wall MI, 264 had inferior (230 inferior + 34 lateral) wall MI, and 73 had RV-MI. Mortality at hospital discharge, 30 days, and 6 months was highest in patients with RV-MI involvement (5.5%, 9.6%, and 12.3%, respectively), intermediate in patients with anterior MI (2.4%, 4.6%, and 7.3%, respectively), and lowest in patients without RV myocardial involvement (0.8%, 1.1%, and 3%, respectively) (P < .05 for hospital discharge and 30 days, P = .1 for 6 months). After adjustment for the CADILLAC score, odds ratio for 30-day morbidity was 5.2 (95% CI 1.6-17, P = .005) for patients with RV-MI versus those without RV-MI. Within the group of patients with RV-MI, complete revascularization of the right coronary artery including the major RV branch was associated with higher rate of RV function recovery by echocardiography and improved 30-day mortality (odds ratio 0.4, 95% CI 0.1-1.05, P = .06). CONCLUSIONS: Right ventricular infarction is an independent risk factor for increased mortality even in these days of primary PCI. Intensive medical therapy including restoring blood flow into the right coronary artery including the major RV branch may improve clinical outcomes.


Subject(s)
Angioplasty, Balloon, Coronary , Heart Ventricles , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Aged , Female , Humans , Male , Middle Aged , Prognosis
16.
Catheter Cardiovasc Interv ; 68(6): 891-6, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17086532

ABSTRACT

OBJECTIVES: The objective of this study was to compare two techniques to treat bifurcation lesions: a single drug-eluting stent (DES) implanted in the main branch combined with balloon dilatation for the side branch vs. stenting of both branches (double stent). BACKGROUND: Percutaneous coronary intervention in coronary bifurcation lesions remains challenging. Although DES reduce restenosis in lesions, the double stent procedure has not shown clear advantages over a single stent with balloon dilation. METHODS: Fifty-three symptomatic patients with true bifurcation lesions were treated using either the double stent technique (n = 25) or one stent in the parent vessel plus balloon angioplasty of the side branch (n = 28). Procedural results and major adverse cardiac event rates (MACE: cardiac death, myocardial infarction, target vessel revascularization (TVR)) were compared. RESULTS: Angiographic procedural success (residual stenosis <30% in both branches) was 75% in the single stent group and 100% in the double stent group (P = 0.01). All differences were due to residual stenosis of the side branch. Clinical follow-up (6-18 months) was available for all patients; 90.5% of patients had a coronary angiography or nuclear stress test. Three patients (11%) in the single stent group and two (8%) in the double stent group had ischemia-driven TVR (P = NS). Asymptomatic angiographic restenosis (>50% diameter stenosis) in the ostium of the side branch was seen in two patients in the double-stent group. At 6 months, MACE-free was comparable between groups (89.3% vs. 88%, P = 0.7). CONCLUSIONS: When treating bifurcation lesions with sirolimus-eluting stents, restenosis following a single stent procedure is comparable to stenting both parent and side branch vessels. Thus, stenting the main-branch lesion, coupled with balloon angioplasty in the side branch, produces a high success rate and good clinical outcomes at 6 months.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Stenosis/therapy , Stents/adverse effects , Aged , Blood Vessel Prosthesis Implantation/methods , Coronary Angiography , Coronary Restenosis/prevention & control , Coronary Stenosis/drug therapy , Coronary Vessels/anatomy & histology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Treatment Outcome
17.
Harefuah ; 145(5): 334-7, 399, 2006 May.
Article in Hebrew | MEDLINE | ID: mdl-16805211

ABSTRACT

This study aimed to evaluate clinical outcomes in octogenarian patients with acute myocardial infarction (AMI) treated by primary angioplasty. We used our clinical database consisting of all patients treated using primary angioplasty (< or = 12 hours) for acute ST elevation myocardial infarction excluding patients with cardiogenic shock. The clinical and angiographic results of non-shock patients, distinguished according to age < 80 years and > or = 80 years, was characterized by higher 30-day mortality among the elderly compared to younger patients (12% versus 3.3%) and overall major cardiac events (17.5% versus 7.4%). Thus, primary angioplasty in the octogenarian patients, albeit feasible and relatively safe, is associated with 30-days death rates that are higher in octogenarian patients as compared to younger patients.


Subject(s)
Angioplasty, Balloon, Coronary , Myocardial Infarction/therapy , Aged, 80 and over , Coronary Angiography , Female , Humans , Male , Myocardial Infarction/mortality , Patient Selection , Survival Analysis , Treatment Outcome
18.
Catheter Cardiovasc Interv ; 67(2): 221-6, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16404750

ABSTRACT

OBJECTIVES: We investigated the impact of primary coronary angioplasty performed during night and compared to the impact of that performed during day-time on outcomes of patients with acute ST elevation anterior wall myocardial infarction (AMI). METHODS: We prospectively followed 273 consecutive patients of whom 160 (58.6%) were treated during day time (8:00 a.m. to 6 p.m.) and 113 (41.4%) were treated "off hours"/at night (6 p.m. to 8 a.m.). Baseline demographics, angiographic factors, and clinical outcomes (death, recurrent AMI, and need for repeat revascularization) were compared between the groups. RESULTS: Baseline clinical characteristics were similar between the two groups. Unadjusted mortality at one-month was significantly higher among patients who were treated during night compared with those treated at day-time (9.7% vs. 3.1% P = 0.03), as was adverse cardiac event rate (15.9% vs. 6.9%; P = 0.02). Multiple logistic regression analysis adjusted for the CADILLAC risk score demonstrated that this score, which includes baseline LVEF, renal failure, Killip class, final TIMI flow, age>65 years, anemia, and the number of coronary vessel diseases, is a significant predictor of one-month mortality, while the effect of time of treatment was borderline (night vs. day; odds ratio 2.7; 95% confidence interval, 0.8-9.4; P = 0.095). CONCLUSIONS: The results of this study indicate that patients with anterior myocardial infarction treated during night time have worse unadjusted short-term clinical outcomes despite no delay from onset of symptoms to actual treatment. Larger studies are needed in order to identify potential contributors to this phenomenon.


Subject(s)
Angioplasty, Balloon, Coronary , Circadian Rhythm , Myocardial Infarction/therapy , Aged , Chi-Square Distribution , Coronary Angiography , Female , Humans , Logistic Models , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Prospective Studies , Risk Factors , Stents , Treatment Outcome
19.
Int J Cardiovasc Intervent ; 7(4): 183-7, 2005.
Article in English | MEDLINE | ID: mdl-16373264

ABSTRACT

The ACIST injection system is an automatic power injection device that allows for online control of injection rate and volume of contrast. Limited data is available whether this technology allows reducing use of contrast and fluoroscopy time. Accordingly, we compared the use of this system to manual injection among 450 consecutive patients who underwent diagnostic coronary angiography and/or angioplasty who were randomly assigned to either manual contrast injection (control; n=198) or to the ACIST system (study group; n=252). The amount of contrast, fluoroscopy and total procedural times were recorded for each patient. In the diagnostic group, the mean total amount of contrast (including wasted) was reduced by 63% when the ACIST was used compared to control (100+/-42 ml versus 163+/-56 ml; P<0.001, respectively). When only the net amount of contrast delivered to the patient was considered, the differences were smaller (20%, P=0.004). During angioplasty, the amount of contrast was also lower in the ACIST group (206+/-65 versus 230+/-69, P=0.008), whereas no difference were noted in net amount of contrast. Fluoroscopy time was significantly shorter in the ACIST group compared to control both during diagnostic catheterization (4.7+/-3.5 min versus 6.3+/-5.5 min, respectively; P=0.014), and angioplasty (16.7+/-9.1 min versus 19.6+/-12.4 min, respectively; P=0.05). Routine utilization of the ACIST system during diagnostic and interventional procedure significantly reduced the total amount of contrast media used and fluoroscopy time.


Subject(s)
Angioplasty, Balloon, Coronary/instrumentation , Contrast Media/administration & dosage , Coronary Angiography/instrumentation , Coronary Disease/diagnostic imaging , Syringes , Aged , Equipment Design , Female , Fluoroscopy , Humans , Injections, Intravenous/instrumentation , Male , Middle Aged , Prospective Studies , Time Factors
20.
Int J Cardiovasc Intervent ; 7(4): 193-8, 2005.
Article in English | MEDLINE | ID: mdl-16373266

ABSTRACT

BACKGROUND: Cardiogenic shock (CS) is a dreadful complication of acute myocardial infarction (AMI) associated with a poor prognosis. Percutaneous coronary intervention (PCI) is widely recommended by current treatment guidelines. AIM: To evaluate the in-hospital and 30-day mortality rate and to determine independent predictors of mortality in a cohort of unselected consecutive patients with CS. METHODS AND RESULTS: Rabin Medical Center cardiac catheterization laboratory database was analyzed between 1/2000 and 8/2003. Fifty of the 472 patients (10.6%) treated using emergent PCI for AMI had cardiogenic shock on presentation. Patients with cardiogenic shock were older, more likely to be female and with higher frequency of co-morbidities. The time from symptom onset until seeking medical treatment was longer in cardiogenic shock patients. In-hospital mortality rate was 48.0% in the cardiogenic shock group as compared to 3.3% in the non-cardiogenic shock group (P<0.0001). In patients with shock, total mortality after 30 days was 52% (26/50). Most of these patients (25/26) died within 48 hours following admission because of refractory cardiogenic shock. A multivariate analysis adjusted for baseline differences showed that age 75 years (odds ratio [OR]: 11; 95% confidence interval [CI]: 1.0-1.24, P=0.05), and the use of GP 2b/3a antagonist (OR: 0.97; 95% CI: 0.95-1.0, P=0.05), were independent predictors of all cause mortality at 30 days. CONCLUSION: Cardiogenic shock remains an important cause of mortality in AMI. Younger age and the use of GP 2b/3a antagonists during primary PCI for cardiogenic shock patients seems to be associated with better clinical outcomes.


Subject(s)
Angioplasty, Balloon, Coronary/methods , Shock, Cardiogenic/therapy , Aged , Coronary Angiography , Electrocardiography , Female , Follow-Up Studies , Hospital Mortality , Humans , Male , Middle Aged , Prospective Studies , Shock, Cardiogenic/diagnosis , Shock, Cardiogenic/mortality , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...